stockrow
Friday 6 November 2026
Export GRDN’s income statement to Excel — free account
Guardian Pharmacy Services, Inc.
GRDN Healthcare Medical Care Facilities
Guardian Pharmacy Services, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.9% from fiscal 2024.
- Revenue
- −1.68%
- EPS
- +133.3%
- Free cash flow
- +88.9%
Quarter to September 2026, against a year earlier
39.72
2.37
−5.63%
Follow GRDN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
38.09 | 44.31 | 39.88 | 38.84 |
P/S ratio |
1.30 | 1.64 | 1.81 | 1.77 | |
P/FCF ratio |
23.26 | 33.93 | 33.23 | 27.19 | |
P/Operating CF |
54.25 | 393.38 | 88.31 | 59.55 | |
P/B ratio |
8.61 | 10.26 | 10.29 | 9.23 | |
Price to Tangible BV |
15.68 | 17.64 | 16.44 | 14.60 | |
EV/Sales |
1.28 | 1.62 | 1.78 | 1.72 | |
EV/EBITDA |
19.47 | 23.49 | 23.90 | 21.27 | |
EV/Operating CF |
18.46 | 26.57 | 26.30 | 21.93 | |
EV/FCF |
22.92 | 33.56 | 32.59 | 26.34 | |
Quick Ratio |
1.04 | 1.10 | 1.26 | 1.27 | |
Current Ratio |
1.38 | 1.46 | 1.65 | 1.65 | |
Net Debt/EBITDA |
(1.80) | (2.74) | (3.40) | (3.86) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
3.95 | 3.83 | 3.66 | 3.30 | |
Operating CF/Net income |
1.65 | 0.46 | 1.37 | 2.32 | |
Capex/Depreciation |
(0.74) | (0.79) | (0.84) | 0.00 | |
Interest Coverage |
188.72 | 114.77 | 134.05 | 141.60 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
13.77% | 17.42% | 16.89% | 16.21% | |
Intangible Assets out of Total Assets |
0.24 | 0.23 | 0.22 | 0.21 | |
Share Based Compensation of Revenue |
0.27% | 0.55% | 0.83% | 0.74% | |
Graham Net Nets |
0.01 | 0.02 | 0.03 | 0.03 | |
Graham Number |
7.88 | 8.38 | 9.80 | 0.00 | |
Earnings Yield |
2.63% | 2.26% | 2.51% | 2.57% | |
Free Cash Flow Yield |
4.30% | 2.95% | 3.01% | 3.68% | |
Revenue per Share |
6.37 | 5.32 | 5.55 | 0.00 | |
Operating CF per Share |
0.55 | 0.10 | 0.47 | 0.00 | |
Capex per Share |
(0.07) | (0.07) | (0.08) | — | |
Free Cash Flow per Share |
0.49 | 0.02 | 0.40 | 0.00 | |
Cash per Share |
1.05 | 1.02 | 1.42 | 0.00 | |
Shareholders Equity per Share |
3.49 | 3.67 | 4.07 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
3.49 | 3.67 | 4.07 | 0.00 | |
Free Cash Flow |
30.37 | 1.31 | 25.14 | 43.37 | |
Working Capital |
60.93 | 74.64 | 100.63 | 115.73 | |
Capital Expenditures |
(4.23) | (4.75) | (4.89) | — | |
Net Current Asset Value |
26.90 | 40.67 | 68.73 | 82.76 | |
EV/EBIT |
25.45 | 30.48 | 30.44 | 26.57 | |
Capex to Sales |
0.01 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
25.82 | 30.82 | 31.04 | 27.43 | |
| Other line items | |||||
Average Receivables |
99.38 | 104.56 | 98.95 | 106.93 | |
Average Payables |
109.31 | 105.11 | 106.60 | 123.99 | |
Average Inventory |
41.95 | 45.30 | 47.30 | 52.46 | |
Average Assets |
366.73 | 380.47 | 399.96 | 440.91 | |
Average Common Equity |
183.95 | 197.82 | 218.66 | 237.61 |
Columns are period end dates · fundamentals updated 5 Nov 2026